We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.
- Authors
Dixon, William G; Carmona, Loreto; Finckh, Axel; Hetland, Merete Lund; Kvien, Tore K; Landewe, Robert; Listing, Joachim; Nicola, Paulo J; Tarp, Ulrik; Zink, Angela; Askling, Johan
- Abstract
The introduction of biological therapies for the treatment of rheumatic diseases has drawn attention to the limitations of traditional means of assessing drug safety. Consequently, a series of European academic biologics registers dedicated to this task have been established. Increasing reliance upon safety data generated from observational drug registers makes it important to convert the lessons learned from such registers into recommendations for rheumatologists embarking upon the establishment of future registers, or analysing and reporting from new and existing registers.
- Publication
Annals of the rheumatic diseases, 2010, Vol 69, Issue 9, p1596
- ISSN
1468-2060
- Publication type
Journal Article
- DOI
10.1136/ard.2009.125526